Type 1 Diabetes TrialNet: Toronto Clinical Center

1 型糖尿病 TrialNet：多伦多临床中心

• 批准号: 9478175
• 负责人: DIANE K WHERRETT
• 金额: $ 44.71万
• 依托单位: HOSPITAL FOR SICK CHLDRN (TORONTO)
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-20 至 2020-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9478175
• 关键词: Adult; Antibodies; Autoantibodies; Autoimmunity; Beta Cell; CD3 Antigens; CTLA4-Ig; Canada; Cell Survival; Clinical; Collaborations; Communities; Community Networks; Complications of Diabetes Mellitus; Consent Forms; Cost efficiency; Data; Data Collection; Development; Diabetes Mellitus; Diabetes prevention; Disease; Effectiveness; Eligibility Determination; Enrollment; Event; Fellowship; Glutamate Decarboxylase; Goals; Human; Institutional Review Boards; Insulin; Insulin-Dependent Diabetes Mellitus; Intervention; Leadership; Link; Methods; Mission; Monitor; Oral; Participant; Pathogenesis; Pathway interactions; Phase; Population; Prevention; Process; Protocols documentation; Randomized; Recombinants; Reporting; Research Personnel; Resource Development; Risk; Role; Site; Study Subject; Therapy trial; Time; Training; Travel; Visit; cost; diabetes risk; follow-up; glucose tolerance; impaired glucose tolerance; improved; innovation; insight; insulin secretion; meetings; member; novel therapeutics; prevent; public health relevance; recruit; retention rate; screening; success; tool

 DESCRIPTION (provided by applicant): Despite effective current therapies for Type 1 diabetes (T1D), significant risks of long term complications of diabetes exist. Multiple studies have demonstrated that autoimmunity associated with type 1 diabetes is found years before its clinical presentation and that T1D can be predicted. The goals of the Type 1 Diabetes TrialNet Study Group are to prevent loss of beta cells through study of the pathogenesis of T1D and trials of therapies to intervene in the process. To reach TrialNet's goal, successful Clinical Centers must maintain and develop highly effective recruitment approaches, encourage participation of subjects in follow up and prevention studies and carry out studies in a highly efficient and accurate manner. In addition, they must contribute to the overall mission by engagement in TrialNet activities and committees and adding clinical and/or scientific expertise. The aims of this application reflect our center's approach to meeting TrialNet's mission: • To describe the progress and function of the Toronto Clinical Center as an innovative and effective TrialNet site that has developed an extensive regional and national network with broad links in the diabetes community. As a result, our site ranks 5th of 18 Clinical Centers in the number of subjects enrolled in screening and monitoring phases of the Pathway to Prevention study with a very high retention rate of over 90%. Careful analysis of the effectiveness of recruitment approaches through the use of reports from TrialNet's Coordinating Center and data collected by our site has allowed us to optimize efforts yielding an increase in the number of subjects screened for the Pathway to Prevention Study over the past 3 years. • To illustrate leadership and collaborative roles in TrialNet efforts such as Dr. Wherrett's leadership of the Study of Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects Study, management of all Canadian regulatory requirements for our site and the Canadian Affiliate Network, and our coordinators' roles in developing materials to support recruitment. • To highlight approaches used to assist Affiliate Sites with training and specialized support such as screening event identification and development. Methods to enhance recruitment and cost efficiency through new links, optimize efficiency of IRB review through the development of shared tools for review and consent documents, monitor the success of recruitment efforts and study conduct are detailed. A proposal for a fellowship to support new clinical researchers in type 1 diabetes is described.

 描述（由申请人提供）：尽管目前 1 型糖尿病 (T1D) 的治疗方法有效，但糖尿病长期并发症的显着风险仍然存在，多项研究表明，与 1 型糖尿病相关的自身免疫在其临床表现和 T1D 出现之前数年就已被发现。可以预见，1 型糖尿病 TrialNet 研究小组的目标是通过研究 T1D 的发病机制并试验干预该过程的疗法来防止 β 细胞丢失，从而成功实现 TrialNet 的目标。临床中心必须维持和开发高效的招募方法，鼓励受试者参与后续和预防研究，并以高效和准确的方式开展研究。此外，他们必须通过参与 TrialNet 活动和委员会来为总体使命做出贡献。该应用程序的目标反映了我们中心实现 TrialNet 使命的方法： • 描述多伦多临床中心作为一个创新且有效的 TrialNet 网站的进展和功能，该网站已开发了广泛的区域和国家网络。网络在糖尿病界具有广泛的联系。因此，我们的网站在参加预防途径研究筛选和监测阶段的受试者数量方面在 18 个临床中心中排名第 5，保留率非常高，超过 90% 通过仔细分析招募方法的有效性。使用 TrialNet 协调中心的报告和我们网站收集的数据使我们能够优化工作，增加过去 3 年预防途径研究筛选的受试者数量。 TrialNet 的努力，例如 Wherrett 博士领导的重组人谷氨酸脱羧酶对新发受试者 1 型糖尿病进展的影响研究、管理我们网站和加拿大附属网络的所有加拿大监管要求以及我们的协调员' 在支持招聘的材料中制定角色 • 重点介绍用于协助附属网站提供培训和专业支持的方法，例如筛选活动识别和开发方法，以提高招聘和成本效率。详细描述了通过新链接、通过开发共享审查和同意文件工具来优化 IRB 审查效率、监控招募工作和研究行为的成功的建议。

项目成果

From Friend to Enemy: Dissecting the Functional Alteration of Immunoregulatory Components during Pancreatic Tumorigenesis.

• DOI: 10.3390/ijms19113584
• 发表时间: 2018-11-13
• 期刊: International journal of molecular sciences
• 影响因子: 5.6
• 作者: Wang HC;Hung WC;Chen LT;Pan MR
• 通讯作者: Pan MR

Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.

• 发表时间: 2018
• 期刊: American journal of cancer research
• 影响因子: 5.3
• 作者: Yu-Feng Tian;Hui-Ching Wang;C. Luo;W. Hung;Yu-Han Lin;Tzu-Yi Chen;Chien-Feng Li;Chen-Yi Lin